The Oxford/AstraZeneca COVID-19 vaccine trial adverse patient event reports /

The Oxford/AstraZeneca COVID-19 vaccine trial adverse patient event reports /

Show other versions (1)
Saved in:
Bibliographic Details
Other Authors: Shakir, Saad (Speaker)
Format: Electronic Audio
Language:English
Published: London : Henry Stewart Talks, 2020.
Series:Henry Stewart talks. Biomedical & life sciences collection. Interviews on Covid-19.
Subjects:
AstraZeneca (Firm)
University of Oxford.
Clinical trials.
COVID-19 (Disease)
COVID-19 (Disease) > Vaccination.
Vaccines > Development.
ChAdOx1 COVID-19 vaccine.
Clinical Trials as Topic.
COVID-19 Vaccines > adverse effects.
COVID-19 > prevention & control.
Pharmacovigilance.
Research Design.
SARS-CoV-2.
Vaccines > adverse effects.
Online Access:https://hstalks.com/bs/4463/
Series
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000nim a2200000 a 4500
001 HST8203
003 UkLoHST
006 m o h
007 cr nna||||||||
007 sr |mnnnnnzne|
008 201204s2020 enk|||||o||h||||||||eng d
028 5 0 |a 8203  |b Henry Stewart Talks 
035 |a (UkLoHST)4463 
040 |a UkLoHST  |b eng  |c UkLoHST 
100 1 |a Shakir, Saad,  |u (Drug Safety Research Unit (DSRU), UK)  |4 spk  |9 87896 
245 1 4 |a The Oxford/AstraZeneca COVID-19 vaccine trial  |h [electronic resource] :  |b adverse patient event reports /  |c an interview with Saad Shakir. 
260 |a London :  |b Henry Stewart Talks,  |c 2020. 
300 |a 1 online resource (1 streaming audio file (14 min.)). 
490 1 |a Interviews on Covid-19,  |x 2056-452X 
500 |a Audio interview. 
500 |a Title from title frames. 
505 0 |a Contents: Mode of action of the Oxford/AstraZeneca RNA vaccine -- Two potential adverse events reported in patients enrolled in the vaccine's phase 3 trial -- Steps undertaken to determine possible causality between the adverse events and the vaccine -- Current status of the trial -- Please note that since the recording of this interview it was determined that "The serious adverse events observed during the trial in these study groups were judged to be unrelated to the study vaccines and occurred at frequencies expected for these conditions in the general population. None of the participants included in this report had any suspected unexpected serious adverse reactions." (Ramasamy et al., The Lancet, November 18, 2020, https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32466-1/fulltext). 
506 |a Access restricted to subscribers. 
538 |a Mode of access: World Wide Web. 
610 2 0 |a AstraZeneca (Firm)  |9 87897 
610 2 0 |a University of Oxford.  |9 87898 
650 0 |a Clinical trials.  |9 87899 
650 0 |a COVID-19 (Disease)  |9 87900 
650 0 |a COVID-19 (Disease)  |x Vaccination.  |9 87901 
650 0 |a Vaccines  |x Development.  |9 87902 
650 2 |a ChAdOx1 COVID-19 vaccine.  |9 87903 
650 2 |a Clinical Trials as Topic.  |9 87904 
650 2 |a COVID-19 Vaccines  |x adverse effects.  |9 87905 
650 2 |a COVID-19  |x prevention & control.  |9 87906 
650 2 |a Pharmacovigilance.  |9 87907 
650 2 |a Research Design.  |9 87908 
650 2 |a SARS-CoV-2.  |9 87909 
650 2 |a Vaccines  |x adverse effects.  |9 87910 
830 0 |a Henry Stewart talks.  |p Biomedical & life sciences collection.  |p Interviews on Covid-19.   |9 87911 
856 4 0 |u https://hstalks.com/bs/4463/ 
856 4 2 |u https://hstalks.com/bs/p/1060/  |3 Series 
999 |c 213923  |d 213922 

Similar Items